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Abstract
Background: It was previously demonstrated that the dipeptide carnosine inhibits growth of cultured cells isolated
from patients with malignant glioma. In the present work we investigated whether carnosine also affects tumor
growth in vivo and may therefore be considered for human cancer therapy.
Results: A mouse model was used to investigate whether tumor growth in vivo can be inhibited by carnosine.
Therefore, NIH3T3 fibroblasts, conditionally expressing the human epidermal growth factor receptor 2 (HER2/neu), were
implanted into the dorsal skin of nude mice, and tumor growth in treated animals was compared to control mice. In
two independent experiments nude mice that received tumor cells received a daily intra peritoneal injection of 500 μl
of 1 M carnosine solution. Measurable tumors were detected 12 days after injection. Aggressive tumor growth in
control animals, that received a daily intra peritoneal injection of NaCl solution started at day 16 whereas aggressive
growth in mice treated with carnosine was delayed, starting around day 19. A significant effect of carnosine on tumor
growth was observed up to day 24. Although carnosine was not able to completely prevent tumor growth, a
microscopic examination of tumors revealed that those from carnosine treated animals had a significant lower number
of mitosis (p < 0.0003) than untreated animals, confirming that carnosine affects proliferation in vivo.
Conclusion: As a naturally occurring substance with a high potential to inhibit growth of malignant cells in vivo,
carnosine should be considered as a potential anti-cancer drug. Further experiments should be performed in order
to understand how carnosine acts at the molecular level.
Background
Carnosine, a dipeptide discovered more than 100 years
ago [1] is a naturally occurring substance synthesized by
endogenous carnosine synthetase. It is present in mam-
malian brain at a concentration between 0.7 and 2.0
mM [2] and reaches concentrations of up to 20 mM in
skeletal muscle [3]. However, not much is known about
its physiological function but several possible roles have
been considered since its first discovery (for detailed
review see [4,5]). Among these functions ph-buffering
[6], metal chelation [7] or neurotransmitter function [8]
have been discussed and the currently most intensively
debated aspects are its potential protective effect against
oxidative stress [9], its likely role as a therapeutic agent
for the treatment of Alzheimer’s disease [10] and its use
as a potential anti-senescence drug [11]. Just recently, it
was demonstrated that carnosine is also able to inhibit
growth of cultured cells isolated from human brain
tumors in cell culture. This effect is not accompanied by
apoptotis or necrosis, but is rather caused by reduced
proliferation [12]. In fact, more recently published data
indicates that reduced proliferation is mediated by an
influence on glycolytic energy metabolism [13]. These
interesting results indicate that carnosine may have an
anti tumorigenic effect. In order to ask, whether carno-
sine might also be able to inhibit growth of tumors in
vivo, we were looking for an experimental model in
order to test a potential therapeutic applicability of car-
nosine. We decided to employ an approved animal
model. This model uses murine NIH3T3 fibroblasts
conditionally expressing human HER2/neu under the
control of a tetracycline-responsive promoter, that
allows turning off of expression under the influence of
tetracycline or its derivatives [14]. HER2/neu, also
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termed neu or erbB-2, belongs to the epidermal growth
factor receptors, involved in cell cycle control and cell
differentiation. Its activation induces several signal trans-
duction pathways including the ras/MAP kinase pathway
[15,16] and the phosphatidyl inositol 3,4,5-triphosphate
kinase/AKT pathway [17]. In the experiments per-
formed, fibroblasts expressing the HER2/neu receptor
were subcutaneously injected into the dorsal skin of
nude mice, resulting in the growth of solid tumors. Two
series of experiments were performed with animals, that
were treated daily with and without carnosine after the
subcutaneous injection of HER2/neu expressing fibro-
blasts. For several weeks, tumor size of animals, receiv-
ing carnosine or NaCl as control, was determined daily.
Methods
Chemicals and reagents
If not stated otherwise all chemicals were purchased
from Sigma (Taufkirchen, Germany).
Cell culture
The tetracycline-controlled cell line NIH3T3-HER2/neu
[14] was cultivated in 75-cm2 flasks (TPP, Trasading,
Germany) in DMEM-Medium (high glucose, Invitrogen,
Karlsruhe, Germany) supplemented, with 10% fetal
bovine serum (FCS Gold; PAA, Cölbe, Germany) and
antibiotics (50 μg/ml streptomycin and 30 μg/ml penicil-
lin) at 37°C and 5% CO2 in humidified air. Harvest of
cells was performed using accutase (PAA) after cells
reached 90% confluency.
Animals
Female nude mice Crl:CD®-1-Foxn1nu were purchased
from Charles River Laboratories (Sulzfeld, Germany).
The animals had access to standard chow (Altrumin pel-
lets; Altrumin GmbH, Lage, Germany) and received
water ad libitum.
Cell based assays
For the determination of ATP concentration and dehydro-
genase activity, cells were cultivated in 96 well plates
(black, clear bottom; μClear, Greiner Bio One, Frickenhau-
sen, Germany) in 200 μl of medium. After 4 hours, med-
ium was exchanged and fresh medium containing
carnosine was added. After 70 hours, intracellular adeno-
sine triphosphate (ATP) concentration was measured by
the CellTiter-Glo Assay (Promega, Mannheim, Germany)
as described [18]. Briefly, after incubation in the absence
or presence of carnosine, medium was removed and
exchanged for 50 μl of fresh medium without carnosine.
At this point it should be noted, that removal of medium
is not necessary and does not change the results. We
included this step in order to make the experiments abso-
lutely comparable to previously published experiments
[12]. Then, 50 μl of CellTiter-Glo reagent were added.
Ten minutes after addition of reagent and incubation at
room temperature, luminescence was determined using a
SpectraMax M5 Multilabel Reader (Molecular Devices,
Ismaning, Germany) in luminescence mode with an inte-
gration time of 500 ms.
For the determination of dehydrogenase activities the
CellTiter-Blue assay (Promega) was employed. Briefly,
before the start of the assay, cells received 100 μl of
fresh medium without carnosine and 20 μl of CellTiter-
Blue reagent. Then, cells were incubated for 90 min at
37°C, 5% CO2 and in humidified air in an incubator.
Finally, fluorescence was determined using an M5 Mul-
tilabel Reader with an excitation wave length of 560 nm
and an emission wave length of 590 nm.
Analysis of mitotic activity
Tumors were excised and fixed in formalin for at least 24
hrs. Then the tissues were dehydrated and embedded in
paraffin wax. Five μm thick serial sections of whole tissue
were cut with a rotation microtome (Leica, Germany),
deparaffinized and stained with Hematoxylin-Eosin
(Merck, Germany). The number of mitoses was counted
at 40 × magnification on a Zeiss Axioplan 2- microscope
(Carl Zeiss, Oberkochen, Germany) with a graded ocular
lens (10 × 10 squares, corresponding to 250 × 250 μm at
40 × magnification). All areas of the tissues were counted
(maximum 10 High Power fields (HPF)) and the rate of
mitosis was calculated as mean per one High-Power field.
Statistical analysis used the students t-test.
Determination of carnosine concentrations in serum
Serum samples were applied onto a MALDI target as 1 μl
droplets. The matrix 2,5-dihydroxybenzoic acid (DHB)
was added as 1 μl droplet (0.5 mol/l stock solution in
methanol) containing pentaglycine (Gly-Gly-Gly-Gly-Gly)
as 5 mmol/l reference standard onto the sample. Positive
ion MALDI-TOF mass spectra were acquired on a Bruker
Daltonics Autoflex workstation (Bruker, Germany). The
system utilizes a pulsed nitrogen laser emitting at 337 nm
and spectra were recorded in the reflector mode under
“delayed extraction” conditions. The extraction voltage
was 20 kV and 128 single laser shots were averaged for
each mass spectrum. The sum of the intensities of the H+,
Na+ and K+ adducts of carnosine (m/z = 227, 249 and
265) and of pentaglycine (m/z = 304, 326 and 342) were
determined for quantitative analysis using the software
“Flex Analysis” version 2.2 (Bruker Daltonics, Germany).
Statistics
All data are expressed as Mean ± standard deviation.
Analysis of significance was performed using the two
sample t-test implemented in the Origin 7.5 Software
(OriginLab Corporation, Northampton, USA).
Results
Carnosine inhibits growth of NIH3T3-HER2/neu cells in
culture
Before the experiments with animals were initiated, it
was asked, whether NIH3T3-HER2/neu cells are
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influenced by carnosine in culture, as demonstrated for
cells from human glioblastoma [12]. Therefore,
NIH3T3-HER2/neu cells were cultivated at an initial
density of 500 cells per well in 96-well plates. Four
hours after the start of the culture, carnosine was added
at different concentrations, and cells were cultivated for
70 hours. Carnosine was added from a 1 M stock solu-
tion in 0.7% NaCl with pH adjusted to that of cell cul-
ture medium (ph = 7.4). Besides, we showed that
addition of carnosine to culture medium does not influ-
ence pH under the culture conditions (37°C and 5%
CO2 [12]). Control cells received a medium containing
the corresponding amount of 0.7% NaCl solution. After
the incubation time, the concentration of ATP was mea-
sured and dehydrogenase activity was determined. As
can be seen in Fig. 1, carnosine reduces dehydrogenase
activity by ~20% at 20 mM, by ~60% at 40 mM and by
~80% at 50 mM carnosine. The concentration of ATP is
reduced by ~30% at 20 mM, by ~70% at 40 mM and by
~80% at 50 mM carnosine. This result is in good agree-
ment with the previously published data from tumor
cells derived from patients with malignant glioma and it
encouraged to ask whether the effect of carnosine on
tumor cell growth may also be observable in vivo.
Intraperitoneal delivered carnosine is detectable in the
blood
In order to answer the question whether intraperitoneal
delivered carnosine will enter the circulation, 3 animals
received an intraperitoneal injection of 500 μl carnosine
(1 M) dissolved in NaCl-Solution (0.7%), ph 7.4. One μl
samples of blood from the tails were analysed for the
presence of carnosine in serum by MALDI TOF mass
spectrometry. The concentrations determined after
injection were 20 ± 5 mM after 15 min, 32 ± 4.2 mM
after 30 min, 10 ± 0 mM after 60 min and 15 ± 0 mM
after two hours. In mice, not treated with carnosine, the
mean concentration determined was 0.097 ± 0,031 mM
and therefore already below the limit of quantification
(0.2 mM) but above the limit of detection (0.05 mM).
Tumor growth in the NIH3T3-HER2/neu animal model
under the influence of carnosine
In two independent experiments (each with 11 animals)
7 × 106 NIH3T3-HER2/neu cells in 100 μl sterile phos-
phate-buffered saline (PBS: 2.7 mM KCl, 1.5 mM
KH2PO4, 140 mM NaCl, 6.5 mM Na2HPO4, pH 7.4)
were injected subcutaneous into the dorsal skin of
female nude mice. The eleven animals in each of the
two series were divided into two groups. One group (6
animals) received a daily intraperitoneal injection of 500
μl carnosine (1 M), dissolved in NaCl-Solution (0.7%),
ph 7.4. The second group (5 animals) was used as con-
trol and received a daily injection of 500 μl of 0.9%
NaCl, pH 7.4. All injections were performed for six days
with a one day break, starting again for six days. Mea-
surable tumors were detected 12 days after injection,
and tumor size was determined by measuring the maxi-
mum and minimum diameters with a caliber rule. The
product of these two diameters was defined as the
tumor size with the dimension mm2. The result of the
two experiments is presented in Fig. 2. As can be seen,
Figure 1 Activity of dehydrogenases and concentration of ATP in NIH3T3-HER2/neu cells cultivated at different concentrations of
carnosine. Cells were incubated for 70 hours in media with carnosine. After incubation ATP concentration as well as dehydrogenase activities
were determined and compared to cells not treated with carnosine.
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progressive tumor development starts at day 16 in con-
trol mice and at day 19 in carnosine mice. Hypothesis
testing using students t-test indicated significances
between treated and control animals from day 17 to day
24 in the first series and from day 17 to day 23, as indi-
cated by the numbers in Fig. 2. Statistical analysis was
not performed after 24 days, since at this time some ani-
mals already reached a tumor size in the control popula-
tion, that was not bearable with animal care. When the
tumors reached the critical size (>220 mm2), the animals
were treated with anhydrotetracycline (animals from
first series; Fig. 2a) or were sacrificed for microscopic
analysis of tumors (animals from second series; Fig. 2b).
Development of tumors after switching off HER2/neu
expression
In the first experimental series (Fig. 2a) the animals
were not sacrificed but were further treated. The treat-
ment protocol and the detailed tumor progression is
presented as additional material. Briefly, the animals
received subcutaneous injections of 100 μl anhydrotetra-
cycline (12 mg/ml) every second day, after tumors
reached a critical size (>220 mm2). These injections turn
off HER2/neu expression and result in the disappear-
ance of tumors. In previous experiments, a reoccurrence
of tumors was observed after 20 to 45 days after anhy-
drotetracycline administration [14]. Since these new
Figure 2 Development of NIH3T3-HER2/neu tumors in animals treated with carnosine. The size of tumors developed from subcutaneous
implanted NIH3T3-HER2/neu cells was determined by measuring maximum and minimum diameters. The tumor size presented is the product of
these two diameters measured at different days after the start of the experiment. Part a and part b of the figure represent two independent
series of experiments. The numbers in the figure indicate the level of significance as determined by student’s t-test (p < ‘number indicated’).
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tumors were reported do be independent from HER2/
neu expression, we wondered whether carnosine may
also have an effect on the reoccurrence of tumors. In
our experiments, all tumors treated with anhydrotetracy-
cline disappeared but no recurrence of tumors was
detected. In addition, one mouse had a spontaneously
diminishing tumor. This animal never received anhydro-
tetracycline, but was continuously treated with carno-
sine, until a second tumor developed, that reached a
critical size around day 60. At this time anhydrotetracy-
cline was injected followed by a significant decrease of
tumor size, indicating that this tumour was still result-
ing from the injected NIH3T3-HER2/neu cells.
Mitotic activity is reduced in tumors from animals treated
with carnosine
In the second series of experiments (Fig. 2b) the animals
were not treated with anhydrotetracycline. Instead, the
animals were sacrificed and the tumours removed in
order to analyse mitotic activity. Paraffin imbedded sec-
tions were analysed as described in the Materials and
Methods section. Microscopy revealed that all tumors
showed a highly malignant mostly sarcoma-like mor-
phology. Compared to the tumours from non-treated
animals, the nuclei of carnosine treated tumours were
less pleomorph (Fig. 3). Most interestingly, the tumours
in the carnosine treated group exhibited a significantly
lower number of mitoses per high power field (14.0 ±
1.58 mitoses/HPF) compared to the tumors from con-
trol mice (21.6 ± 2.19 mitoses/HPF; P < 0.0003).
Discussion
The search for potent anticancer drugs is still a huge
challenge. The two most challenging aspects are on
one hand to find drugs with minor side effects and on
the other hand to find substances that are able to pre-
vent growth of tumors that can not be successfully
treated yet. Carnosine is a highly interesting candidate
with regard to both aspects. Firstly, carnosine is a natu-
rally occurring substance that is present in muscle and
other organs. Secondly, experiments with cultured cells
from non-curable malignant glioma demonstrated that
carnosine is able to diminish proliferation of these
cells. Just recently, it was demonstrated that carnosine
inhibits glycolysis and ATP synthesis in tumor cells in
culture [13]. This observation is in contrast to the
well-known fact that in normal cells carnosine
improves both processes [19]. The basic difference with
regard to energy metabolism between tumor cells and
normal cells have been described almost a century ago
and are known as the Warburg effect [20]. The mole-
cular mechanisms of this effect are still not completely
understood. In fact, the study of the mechanisms, on
how carnosine affects normal and tumor cell energy
metabolism differentially, may help to exploit the basic
differences, and may suggest a way for the creation of
a knowledge-based strategy to fight cancer without
affecting normal cells [21]. However, and first of all, it
had to be asked whether carnosine can be administered
as a drug. In the present study, we therefore investi-
gated whether carnosine may in fact prevent growth of
tumor cells in an established mouse model based on
NIH3T3 cells expressing the oncogene HER2/neu
[14,22]. HER2/neu belongs to the human epidermal
growth factor receptor family (HER) of tyrosine
kinases. It was first described to be overexpressed in
25-30% of breast cancers, but its overexpression is also
seen in subsets of gastric, esophagal and endometric
cancers and in some cancers of the oropharynx, the
lung and the bladder (for review see [23]). Just rece-
cently, it was demonstrated that HER2 is also
expressed in glioblastoma patient samples [24]. In addi-
tion, Herceptin, a recombinant humanised anti-HER2/
neu antibody, can induce cell death in cell lines derived
from glioblastomas [25]. In the mouse model employed
Figure 3 Microscopic images from tumors stained with Hematoxylin-Eosin from an animal treated with carnosine (right) and from a
control animal treated with NaCl solution (left). Many mitotic figures are seen in the tumor from the non-treated animal compared to the
tumor from the treated animal. Pictures were taken at an original magnification of 400×.
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in the present study, expression of HER2/neu is
strongly required for tumor growth. Switching off
expression by the administration of anhydrotetracycline
results in rapid tumor regression. Therefore, it is
tempting to speculate that carnosine also affects HER2/
neu expression, but recent data more strongly indicates
that carnosine exhibits its effect at the level of glycoly-
sis, depleting ATP production, finally resulting in
reduced proliferation [13]. In the present work the anti
proliferative effect of carnosine in vivo is demonstrated
by the reduced growth of tumors in treated animals
and by the smaller number of mitotic cells in treated
tumors. One interesting challenge is now, how to
enhance the local concentration of carnosine in hope
to get a stronger effect on tumor growth. In fact, the
carnosine concentration in the serum of treated ani-
mals after ~26 days of treatment and 24 hours after
the last injection is not significantly different from the
carnosine concentration in the serum of animals not
treated with carnosine (data not shown). We also do
not know whether the continuous administration of
carnosine may induce carnosinase, the degrading
enzyme, that in humans is known to be secreted from
the liver into the serum [26]. Of course, an intratu-
moral injection of carnosine might have been a possibi-
lity but this would have made the determination of
tumor size in the experiments presented difficult. Con-
sidering a clinical application of carnosine, an intratu-
moral injection of carnosine or the implantation of
wafers (e.g. into the resection cavity of a surgically
excised tumor in the case of malignant gliomas), that
continuously release carnosine, may be discussed.
However, discussing a potential clinical application, we
should not withhold, that two minor tumors developed
in two carnosine treated mice of the first series and
one minor tumor in two carnosine treated mice of the
second series, close to the time, when the primary
tumor already had reached its maximum size (data not
shown). The additional tumors were very small and
regressed after administration of anhydrotetracycline.
Although they may have been initiated in the vicinity
of the primary tumor by a small number of cells subcu-
taneously introduced by the injection, it cannot be
ruled out, that they originated from cells that have
migrated from the primary tumor. Whether carnosine
may induce a migratory potential, is pure speculative
and needs further experimental data.
One puzzling observation in the course of the experi-
ments was the complete disappearance of one tumor in
a mouse, that was continuously treated with carnosine.
A careful examination of the mouse did not reveal any
sign of an accidental injection that is usually detectable
even after several days. In addition, regression needs
several repeated injections and cannot just be caused by
one accidental injection. Therefore, it must be con-
cluded that the tumor regressed under the continuous
treatment with carnosine. Although this tumor reap-
peared after 50 days of treatment, this observation is a
highly interesting one with regard to a possible use of
carnosine in human tumor therapy.
Conclusions
The data presented prove that carnosine has an antipro-
liferative effect on malignant cells in vivo as demon-
strated before in culture. Therefore, carnosine should be
considered as a potential anticancer agent, especially
since it is a naturally occurring substance. It is now very
important to analyse how carnosine inhibits prolifera-
tion and whether it may be a useful drug for anticancer
therapy in humans.
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